Rheumatoid Arthritis: A Comprehensive Review of Pathogenesis, Diagnosis, and Treatment Strategies
Keywords:
Rheumatoid arthritis, Autoimmune disease, Disease-modifying antirheumatic drugs (DMARDs), Synovial inflammation, Early diagnosis, Treat-to-target strategy, Personalized medicineAbstract
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease primarily affecting the synovial joints, leading to inflammation, pain, and potential long-term disability. This comprehensive review explores the current understanding of RA, encompassing its epidemiology, pathophysiology, clinical presentation, diagnostic approaches, and management strategies. Recent advances in the field have significantly improved our ability to diagnose RA early and initiate effective treatment, potentially altering the disease course. This article critically examines the latest research on RA, including novel therapeutic targets, personalized medicine approaches, and the impact of lifestyle factors on disease progression.
References
McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389(10086):2328-2337.
Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001.
Firestein GS, McInnes IB. Immunopathogenesis of Rheumatoid Arthritis. Immunity. 2017;46(2):183-196.
Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581.
Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68(1):1-26.
Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685-699.
Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-187.
Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017;389(10086):2338-2348.
Deane KD, Holers VM. The Natural History of Rheumatoid Arthritis. Clin Ther. 2019;41(7):1256-1269.
Winthrop KL, Weinblatt ME, Crow MK, et al. Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. Ann Rheum Dis. 2020;79(1):88-93.
Nikiphorou E, Lempp H, Kohrt BA. Treatment failure in inflammatory arthritis: time to think about syndemics? Rheumatology (Oxford). 2019;58(9):1526-1533.
Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage. 2013;21(1):16-21.
Yeoh N, Burton JP, Suppiah P, Reid G, Stebbings S. The role of the microbiome in rheumatic diseases. Curr Rheumatol Rep. 2013;15(3):314.
Mankia K, Emery P. Preclinical Rheumatoid Arthritis: Progress Toward Prevention. Arthritis Rheumatol. 2016;68(4):779-788.
Mahmood S, Lesuis N, van Tuyl LH, van Riel P, Landewé R. Quality in rheumatoid arthritis care. Best Pract Res Clin Rheumatol. 2015;29(4-5):664-679.
